MI Appoints New President of Business Development to Expand Array Markets Including the Rapidly Developing High-Throughput Arrayed Screening and Diagnostics Sectors

Share Article

New Microarrays Inc. President of Business Development Andrew Jennings Sees Boundless Growth Opportunities for the Company in Increasing Demand for MI Proprietary Technology Which Enables Moving Traditional Microtiter Plate Assays to High Efficiency Arrays

Microarrays Inc (MI) today announced the appointment of Andrew Jennings as President of Business Development to lead the expansion of MI’s commercial activities. With more than 20 years developing strong sales, marketing and business development organizations for technology companies, Andrew lead the sales organization for Open Biosystems (now Thermo Fisher Scientific) for the last five years. During this time, he spearheaded innovative commercial initiatives to partner with customer organizations, growing significantly ahead of the general biotechnology market and much larger competitors.

“I believe MI’s proprietary array techniques and game-changing approach to the manufacture and development of microarray technology empowers our customers to better serve the biological research, detection and diagnostics markets,” said Andrew Jennings. “Our early partnerships have allowed MI to mature its products and services, and we will build on this to serve more customers and market segments. I’m excited to be a part of the MI team leading the field in the rapidly developing field of arrayed screening.”

About MI
MI’s corporate mission is to advance array-based technologies for biological research, detection and diagnostics. In diligent pursuit of this goal, MI has progressed to the forefront of development and commercialization of microarray and array-based technologies. MI technology innovations have applications in the fields of analyte testing, diagnostics, identification of viral and bacterial pathogens, and personalized medicine.

Founded in 1999, MI has its origins in the Microarray Core facility of the Vanderbilt-Ingram Comprehensive Cancer Center in Nashville, Tennessee. As a result of the growing expertise, proficiency and printing innovations developed at the Cancer Center, MI was established as an autonomous company in November 2000 and has been privately held since May 2010.

In May 2008, MI relocated to the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. This move allowed MI the much needed ability to expand its capacity, as well as foster close relationships in the exciting, growing field of personalized medicine.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Andrew Jennings
Visit website